Den foreslåede tætte overvågning, herunder neurologisk undersøgelse for hver 20 dages behandling, vil muligvis mindske denne risiko, men vil være en betydelig byrde for både patient og læge.
The proposal of close monitoring including neurological examination after each 20 day treatment cycle might reduce these risks, but is a measure of considerable burden to both patient and doctor.